A small Swedish biotech lands a potentially bill

NanoDetection secures global rights to antibody

The world’s smallest smart ring signals Oura’s move from wellness tracking toward proactive, personalized health guidance. Wearable technology is usually patterned as more sensors, more features, more data. Now, health tech company ŌURA is taking a different approach. Its newly unveiled Oura Ring 5 is 40% smaller than its predecessor, making it what the company calls the world’s smallest smart ring. Yet the significance of the launch isn’t really about size. Instead, ŌURA’s latest device points to a trend unfolding across the longevity sector: the transition from tracking health to helping people protect it actively [1]. Most wearables have become very good at telling users what happened yesterday. You slept poorly. Your heart rate was elevated. Your activity levels dropped. Useful information, certainly, but information alone rarely changes outcomes. The next generation of health technology is increasingly confronting a more difficult question: what happens next? “Oura Ring 5 is a big step toward our vision of giving every body a voice,” said Tom Hale, CEO at ŌURA. “By reimagining Oura Ring 5 to be smaller, easier to wear, and pairing it with our most advanced software yet, we’re making it possible for many more people to wear Oura every day…

New findings suggest OrsoBio’s energy-burning

Cathie Wood’s firm joins Cellares’ $277m fun

Rokit Healthcare announced it has received clinic

Tectonic Therapeutic has completed enrollment in

NeuroSense announced that the Korean Intellectual

Haut.

Heartseed has begun dosing patients in its domest

Melbourne-based Lateral Pharma announced that a p

Immorta Bio published a peer-reviewed study in th

Osteoboost’s State of Bones Report points to g

A mitochondrial therapy that leaves hunger untou

New Longevity Show blog argues that wellness pro

A 2,000-person study at Beijing’s renowned 301

New resource aims to help users navigate more th

Ab Science announced that new analyses from its p

Linnaeus Therapeutics announced that its lead can

MetaShape Pharma reported preclinical findings sh

AcCELLerated Biologics announced on 9 June 2026,

The Lung Cancer Research Foundation (LCRF), in co

Junevity has engaged Sunrise BioVentures as advis

New collaboration shifts the focus from slowing

The company’s latest platform update brings FD

Immorta Bio says the future of medicine may lie

C2N Diagnostics and SouthGenetics aim to bring e

Researchers from across disciplines will gather

Alterity Therapeutics reported a successful End-o

Houston-based Coya Therapeutics has started the b

AlzeCure has entered a collaboration and out-lice

MetaVia presented late-breaking Phase 1 and precl

Immorta Bio presented its AI-enabled, personalize

Based in Encinitas, Calif.

New funds and strategic collaboration with Merck

As regenerative medicine advances, preserving yo

New dried blood spot kit could make large-scale

IIOL Executive Director Tina Woods explains why

First patient dosed in Phase 1 trial testing epi

Rokit Healthcare said it appointed Nadan Lee as c

MitoRx presented preclinical results for its lead

Largest-ever analysis of knee osteoarthritis cha

$15 million funding signals growing demand for p

With their healthspan eroding in real time, Vall

New clinical intelligence system aims to help ph

Muna Therapeutics announced on 4 June 2026 that a

Celularity and Fountain Life announced that Cenpl

Hengrui Pharma and Kailera Therapeutics presented

OrsoBio will present clinical and preclinical dat

Antag Therapeutics presented Phase 1 and preclini